Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate

Annals of Oncology

Volumn 15, Issue 6, 2004, Pages 974-978

  Tay, M H ^a   Kaufman, D S ^b   Regan, M M ^a   Leibowitz, S B ^a   George, D J ^a   Febbo, P G ^a   Manola, J ^a   Smith, M R ^b   Kaplan, I D ^c   Kantoff, P W ^a   Oh, W K ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Bicalutamide; Finasteride; Potency; Prostate

Indexed keywords

ANDROGEN; BICALUTAMIDE; FINASTERIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADVANCED CANCER; AGED; ARTICLE; BODY WEIGHT DISORDER; BREAST TENDERNESS; CANCER PATIENT; CANCER SURVIVAL; CASTRATION; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; ERECTILE DYSFUNCTION; FATIGUE; FOLLOW UP; GYNECOMASTIA; HORMONAL THERAPY; HUMAN; IMPOTENCE; LIBIDO; LIBIDO DISORDER; LIVER DYSFUNCTION; MALE; MEDICAL ASSESSMENT; PENIS ERECTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; QUESTIONNAIRE; SEXUAL FUNCTION; TIME; TREATMENT FAILURE; WEIGHT REDUCTION;

ADENOCARCINOMA; AGED; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FINASTERIDE; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 3442881953     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh221     Document Type: Article

References (18)

1. Smith MR. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 2002; 60: 79-85 (Discussion 86).
2. Iversen P. Antiandrogen monotherapy: indications and results. Urology 2002; 60: 64-71.
3. Iversen P. Quality of life issues relating to endocrine treatment options. Eur Urol 1999; 36 (Suppl 2): 20-26.
4. Smith MR, Fallon MA, Goode MJ. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 2003; 61: 127-131.
5. Geller J. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 1990; 71: 1552-15555.
6. Labrie F. Intracrinology. Mol Cell Endocrinol 1991; 78: C113-118.
7. Brufsky A, Fontaine-Rothe P, Berlane K et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 1997; 49: 913-920.
8. Talcott JA, Clark JA, Stark PC et al. Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 2001; 166: 494-499.
9. Steward AW. Functioning and Well Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press 1992.
10. Soloway MS, Matzkin H. Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. Cancer 1993; 71: 1083-1088.
11. Arai Y, Yoshiki T, Yoshida O. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol 1990; 144: 1415-1419.
12. Schellhammer P, Sharifi R, Block N et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. Urology 1995; 45: 745-752.
13. Rittmaster RS, Norman RW, Thomas LN et al. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996; 81: 814-819.
14. Andriole G, Lieber M, Smith J et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995; 45: 491-497.
15. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224.
16. Hanlon AL, Diratzouian H, Hanks GE. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 297-303.
17. Zietman AL, Tibbs MK, Dallow KC et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol 1996; 40: 159-162.
18. Potosky AL, Knopf K, Clegg LX et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19: 3750-3757.